Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00291187 · ClinicalTrials.gov registry record · Phase 3
VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 411
- Enrollment target
NCT00291187 is a Phase 3 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 411 participants.
The verdict
NCT00291187, a Phase 3 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 411 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.
Interventions
- DRUG Placebo
- DRUG 20 mg VEC-162
- DRUG 50 mg VEC-162
- DRUG 100 mg VEC-162
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00291187
The ClinicalTrials.gov registry entry for NCT00291187 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 411 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00291187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00291187 about?
NCT00291187 is a clinical study titled "VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia". The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.
What is the current status of trial NCT00291187?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 411 participants. The study started on 2006-02. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00291187?
The interventions under investigation include: Placebo (DRUG), 20 mg VEC-162 (DRUG), 50 mg VEC-162 (DRUG), 100 mg VEC-162 (DRUG).
Who is sponsoring clinical trial NCT00291187?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.